Canlyniadau Chwilio

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia gan Piyanuch Kongtim, Uday Popat, Antonio Jiménez, Sameh Gaballa, Riad El Fakih, Gabriela Rondón, Julianne Chen, Carlos Bueso-Ramos, Gautam Borthakur, Naveen Pemmaraju, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Amin M. Alousi, Chitra Hosing, Paolo Anderlini, Issa F. Khouri, Partow Kebriaei, Börje S. Andersson, Betül Oran, Katayoun Rezvani, David Marín, Elizabeth J. Shpall, Richard E. Champlin, Stefan O. Ciurea

Cael y testun llawn

Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia gan Ashkan Emadi, Rawan Faramand, Brandon Carter‐Cooper, Seda S. Tolu, Laurie Ford, Rena G. Lapidus, Meir Wetzler, Eunice S. Wang, Arash Etemadi, Elizabeth A. Griffiths

Cael y testun llawn Cael y testun llawn

Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without... gan Kristie A. Blum, Zhongfa Liu, David Lucas, Ping Chen, Zhiliang Xie, Robert A. Baiocchi, Donald M. Benson, Steven M. Devine, Jeffrey J. Jones, Leslie A. Andritsos, Joseph M. Flynn, Christoph Plass, Guido Marcucci, Kenneth K. Chan, Michael R. Grever, John C. Byrd

Cael y testun llawn

Activity of azacitidine in chronic myelomonocytic leukemia gan Rubens Costa, Haifaa Abdulhaq, Bushra Haq, Richard K. Shadduck, Joan Latsko, Mazen S. Zenati, Folefac Atem, James M. Rossetti, Entezam Sahovic, John Lister

Cael y testun llawn Cael y testun llawn

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid... gan Talha Badar, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Jorge E. Cortés, Naveen Pemmaraju, Sherry R. Pierce, Kate J. Newberry, Naval Daver, Srđan Verstovšek

Cael y testun llawn

Myelodysplastic Syndromes gan P Greenberg, Eyal C. Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, James M. Foran, Karin Gaensler, Guillermo Garcia‐Manero, Steven D. Gore, David Head, Rami S. Komrokji, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Mark A. Schroeder, Paul J. Shami, Richard M. Stone, James E. Thompson, Peter Westervelt

Cael y testun llawn Cael y testun llawn

Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia gan Tapan M. Kadia, Stefan Faderl, Farhad Ravandi, Elias Jabbour, Guillermo Garcia‐Manero, Gautam Borthakur, Alessandra Ferrajoli, Marina Konopleva, Jan A. Burger, Xuelin Huang, Xuemei Wang, Sherry Pierce, Mark Brandt, Jennie B. Feliu, Jorge E. Cortés, Hagop M. Kantarjian

Cael y testun llawn

Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia gan Jianyong Li, Yaoyu Chen, Yu Zhu, Jianfeng Zhou, Yanli Xu, Yan Li, Kang Yu, Ling Pan, Jianmin Wang, Jia-Hua Ding, Jian Gu, Shanhua Zhou, Jinning Shi, Ming Hong, Ji Xu, Liang-Qin Pan, Limin Duan, Run Zhang, Sujiang Zhang, Huayuan Zhu, Hua Lu, Peng Liu, Hongxia Qiu, Hanxin Wu, Sixuan Qian

Cael y testun llawn Cael y testun llawn

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients gan Stefan Faderl, Farhad Ravandi, Xuelin Huang, Xuemei Wang, Elias Jabbour, Guillermo Garcia‐Manero, Tapan M. Kadia, Alessandra Ferrajoli, Marina Konopleva, Gautam Borthakur, Jan A. Burger, Jennie B. Feliu, Hagop M. Kantarjian

Cael y testun llawn Cael y testun llawn

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies gan Eric Laille, Tao Shi, Guillermo Garcia‐Manero, Christopher R. Cogle, Steven D. Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, Kyle J. MacBeth

Cael y testun llawn Cael y testun llawn

Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine gan Theresa D. Ahrens, Sylvia Timme, Jens Hoeppner, Jenny Ostendorp, Sina Hembach, Marie Follo, Ulrich T. Hopt, Martin Werner, Hauke Busch, Melanie Boerries, Silke Laßmann

Cael y testun llawn Cael y testun llawn

DNA hypomethylation-mediated activation of<i>Cancer/Testis Antigen 45</i>(<i>CT45</i>) genes is associated with disease progression and reduced survival in epithelial ovarian cance... gan Wa Zhang, Carter J. Barger, Petra A. Link, Paulette Mhawech‐Fauceglia, Austin Miller, Stacey N. Akers, Kunle Odunsi, Adam R. Karpf

Cael y testun llawn

Epigenome-Based Personalized Medicine in human Cancer gan Wenji Yan, James G. Herman, Mingzhou Guo

Cael y testun llawn

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome gan Iskra Pusic, Jaebok Choi, Mark A. Fiala, Feng Gao, Matthew Holt, Amanda F. Cashen, Ravi Vij, Camille N. Abboud, Keith Stockerl‐Goldstein, Meghan A. Jacoby, Geoffrey L. Uy, Peter Westervelt, John F. DiPersio

Cael y testun llawn

Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells gan Shota Tanaka, Mika Hosokawa, Kumiko Ueda, Seigo Iwakawa

Cael y testun llawn Cael y testun llawn

An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma gan Qian Mei, Meixia Chen, Xue-Chun Lu, Xiang Li, Feng Duan, Maoqiang Wang, Guangbin Luo, Weidong Han

Cael y testun llawn Cael y testun llawn

Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma gan Richard G. Everson, Joseph Antonios, Dominique N. Lisiero, Horacio Soto, Rudi Scharnweber, Matthew C. Garrett, William H. Yong, Ning Li, Gang Li, Carol A. Kruse, Linda M. Liau, Robert M. Prins

Cael y testun llawn Cael y testun llawn

RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model gan Angela Rivers, Kestis Vaitkus, Maria Armila Ruiz, Vinzon Ibañez, Ramasamy Jagadeeswaran, Tatiana Kouznetsova, Joseph DeSimone, Donald Lavelle

Cael y testun llawn Cael y testun llawn

Guadecitabine (SGI‐110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin gan Yuting Kuang, Anthony B. El-Khoueiry, Pietro Taverna, Mats Ljungman, Nouri Neamati

Cael y testun llawn Cael y testun llawn

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma gan Deepa Kolaseri Krishnadas, Suzanne Shusterman, Fanqi Bai, Lisa Diller, Janice E. Sullivan, Alexandra Cheerva, Rani E. George, Kenneth G. Lucas

Cael y testun llawn